Laboratorios Del Dr. Esteve S.a.

Esteve Laboratorios Dr. Esteve S.a.

Laboratories Del Dr. Esteve S.a.

Josep Mas Prió

Alberto Dordal Zueras

Antoni Torrens Jover

Luz Romero Alonso

Helmut Heinrich Buschmann

Susana Yenes Minguez

Monica Garcia Lopez

Susana Yenes Mínguez

Maria Angeles Fisas Escasany

Jordi Frigola Constansa

Jose Aurelio Castrillo Perez

Antoni Jover Torrens

Helmut-Heinrich Buschmann

Mónica Garcia Lopez

Helmut Henrich Buschmann

Helmut H Buschmann

The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.

[object Object]

The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline propyl sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.

5-HT7 receptor antagonists

It was an object of the present invention to provide novel compounds that are suitable in particular as active substances in medicaments, preferably in medicaments for the regulation of neuropeptide Y receptors, particularly preferably of neuropeptide Y5 (NPY5) receptor, for the regulation of food ingestion (food intake), preferably for the prophylaxis and/or treatment of disorders of food ingestion, such as obesity, anorexia, cachexia, bulimia or type II (non insulin dependent) diabetes, for the prophylaxis and/or treatment of disorders of the peripheral nervous system, disorders of the central nervous system, anxiety, depression, cognitive disorders, preferably memory disorders, cardiovascular diseases, pain, epilepsy, arthritis, hypertensive syndrome, inflammatory diseases, immune diseases and other NPY5 mediated disorders in animals and mammals, including man. Said object was achieved by providing 1,4-disubstituted piperidine compounds of general formula (I) wherein the substituents are defined in claim. 

2-'4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine derivatives and related compounds as neuropeptide Y5 (NPY5) ligands for the treatment of obesity

The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.

The present invention relates to Benzoxazinone-derived compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals.

Benzoxazinone-derived compounds, their preparation and use as medicaments

5-HT7 receptor ligands

Growing community of inventors

Barcelona, Spain

Josep Mas Prió